-+ 0.00%
-+ 0.00%
-+ 0.00%

Changes in US stocks | Avcatec tablets approved for listing Cytokinetics (CYTK.US) surged more than 10%

Zhitongcaijing·12/22/2025 15:57:05
Listen to the news

The Zhitong Finance App learned that on Monday, Cytokinetics (CYTK.US) surged more than 10%, continuing to reach a new high during the year, and is now at $69.34. According to the news, recently, the China Drug Administration approved the marketing of the Class 1 innovative drug Avcatel tablets (trade name: xingshupin) declared by Cytokinetics, Incorporated. The drug is used to treat adult patients with obstructive hypertrophic cardiomyopathy (HCM) with grade II-III cardiac function classification by the New York Heart Association (NYHA) to improve motor ability and symptoms.